CogState (CGS.AX) Azione Prezzo
CogState Prezzo
Negli ultimi 19 anni CogState ha aumentato il fatturato del 20,0% all'anno, raggiungendo 53,09 Mio. USD. L'utile per azione è cresciuto del 8,5% all'anno negli ultimi 16 anni. Per CogState, il margine netto del 19,1% risulta in aumento rispetto al 16,0% di alcuni anni fa. Al prezzo attuale il rendimento da dividendo è pari a circa il 1,20%. Il payout ratio è pari a circa il 34% degli utili. Il target di prezzo di consenso a 12 mesi per CogState è 2,15 USD, circa il 10,0% sotto il prezzo attuale di mercato. Su 6 analisti, 5 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
CogState Prezzo delle azioni
CogState Azione e analisi azionaria
Domande frequenti sull'azione CogState
CogState Ltd is a leading provider of cognitive testing services for clinical trials, academic research, and healthcare. The company's business model revolves around using their digital tools and technologies to measure and enhance cognitive function in patients. By collaborating with pharmaceutical companies, academic institutions, and healthcare organizations, CogState Ltd aims to improve patient outcomes and accelerate the development of new treatments. With their expertise and extensive database, CogState Ltd offers customized solutions and prognostic insights to address the cognitive challenges faced in various industries.
CogState Ltd is primarily active in the healthcare and pharmaceutical industries.
The main competitors of CogState Ltd in the market are Cambridge Cognition Holdings PLC, Neurotrack Technologies Inc., and CogniFit Ltd. These companies also specialize in cognitive assessment and provide similar solutions and services. However, CogState Ltd distinguishes itself through its innovative technologies and partnerships, including collaborations with leading pharmaceutical companies. With its strong focus on enhancing the understanding and measurement of cognitive function, CogState Ltd continues to remain competitive in the market and deliver valuable solutions to its clients.
CogState Ltd is a renowned company with a rich history and background. Founded in 1999, CogState specializes in cognitive testing and offers innovative solutions to improve brain health assessment. With its headquarters in Melbourne, Australia, the company has expanded its global presence, serving various sectors including pharmaceuticals, biotechnology, and academic research. CogState has developed cutting-edge technologies and software platforms to deliver accurate and efficient cognitive assessments, benefiting patients, researchers, and professionals worldwide. Known for its advanced cognitive testing methods and commitment to enhancing brain health, CogState Ltd has established itself as a trusted industry leader.
CogState Ltd has achieved several significant milestones in its history. One key achievement is the development and commercialization of its pioneering cognitive testing technology, known as the CogState Computerized Cognitive Assessment Tool (CCAT). This innovative tool is widely utilized in clinical trials and research studies worldwide, enabling precise and objective measurement of cognitive function. Additionally, CogState Ltd has successfully established strategic partnerships with leading pharmaceutical companies, academic institutions, and healthcare providers, facilitating the widespread adoption of its solutions. The company continues to thrive through ongoing research and development, further cementing its position as a global leader in cognitive assessment technology.
CogState Ltd is primarily present in Australia, the United States, and Europe.
CogState Ltd represents a set of core values and a corporate philosophy that drive its operations. The company is committed to innovation, delivering cutting-edge solutions in the fields of cognitive assessment and clinical trials. CogState prioritizes integrity, ensuring transparent and ethical practices in all aspects of its business. With a focus on collaboration, CogState fosters strong partnerships to drive mutual success. The company values dedication to excellence, constantly striving for improvement and delivering high-quality products and services. CogState fosters a customer-centric approach, prioritizing customer satisfaction and delivering tailored solutions. Overall, CogState Ltd embodies a commitment to innovation, integrity, collaboration, excellence, and customer-centricity in its corporate philosophy.
Gli analisti fissano attualmente un prezzo obiettivo medio di 2,15 USD per l’azione CogState (mediana: 2,15 USD), pari a -10,0 % rispetto all’ultimo prezzo. Il consenso si basa su 6 giudizi di analisti.
7 analisti valutano attualmente l’azione CogState: 6 raccomandano l’acquisto, 1 la tenuta e 0 la vendita. Per il 2026 gli analisti si aspettano per CogState ricavi pari a 128,65 Mio. USD e un utile per azione di 0,09 USD.
Convertita al tasso di cambio attuale, l’azione CogState quota 2,13 EUR (2,39 USD).
L’azione CogState (CGS.AX) è quotata su 2 borse, tra cui: ASX (CGS.AX).
CogState Ltd is an innovative company specializing in the development and marketing of cognitive testing solutions. The company offers a wide range of products and services that can be used in the fields of pharmaceutical research, clinical diagnostics, and sports performance optimization. The three main business divisions of CogState Ltd include research and development of cognitive tests, clinical diagnostics and monitoring of patients with neurodegenerative disorders, and solutions for improving sports performance. The company's products are rooted in today's technology, as they are exclusively offered online. They allow for remote diagnosis and supervision of patients, saving time for therapists and improving diagnostic accuracy. The company's proprietary software platform enables researchers to effectively manage their studies and present study results in a concise format. CogState Ltd has a strategy in place to continue offering unique and expanding product offerings, allowing the company to remain a strong competitor in the industry.
Il attesa fatturato di CogState ammonta a 128,65 Mio. USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di CogState ammonta a 16,22 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di CogState è attualmente 25,60. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione CogState.
Il rapporto prezzo/fatturato (P/S) di CogState è attualmente 3,23. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione CogState.
Il Quality Score AlleAktien per CogState è 6/10.
L'ISIN di CogState è AU000000CGS8. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il ticker di CogState è CGS.AX. Con questo simbolo di borsa vengono negoziate le azioni CogState in borsa.
Azione CogState
Gruppo di pari di CogState
CogState Ticker
CogState FIGI
Altre metriche e analisi di CogState in Deep Dive.
La nostra analisi azionaria dell'azione CogState include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di CogState. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: